Systemic toxicity and off-target effects limit the therapeutic index of conventional cancer immunotherapies, hindering their ability to effectively target tumors while sparing healthy tissue. Broad tissue distribution of biologics can lead to significant side effects, reducing the potential for effective treatment.

Voro Therapeutics is developing the PrimeBody platform, an antibody-based therapeutic approach designed to selectively activate myeloid immune cells within the tumor microenvironment (TME). PrimeBody utilizes multi-specific antibodies that remain masked until they reach the TME, minimizing systemic toxicity and maximizing tumor specificity. By combining tumor-activation and targeted delivery, PrimeBody orchestrates both innate and adaptive immune responses, potentially leading to long-term cancer immunity. The modular design incorporates a tumor-targeting element, a protease-cleavable linker, a myeloid immune stimulator, and a myeloid immune checkpoint inhibitor, all within a single agent.

Multi-specific antibody platform enabling single-agent activity with high tumor specificity.

Proprietary masking technology to prevent off-target activation in healthy tissues.

Protease-cleavable linker for selective activation within the tumor microenvironment.

Modular design allowing for incorporation of various immune modulators and targeting elements.

Myeloid immune checkpoint inhibitor component to enhance immune response within the TME.

Myeloid immune stimulator component to activate myeloid cells.

Potential to induce both innate and adaptive immune responses for long-term cancer immunity.

The primary target audience includes cancer patients and clinicians seeking more effective and less toxic immunotherapeutic options, as well as pharmaceutical companies developing next-generation cancer treatments.